Alternative pharmacological interventions that limit myocardial infarction

Current Medicinal Chemistry

Volumn 15, Issue 30, 2008, Pages 3204-3213

  Andreadou, I ^a   Iliodromitis, E K ^b   Farmakis, D ^c   Tsotinis, A ^a   Kremastinos, D Th ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c INSTITUTE OF BIOLOGY   (Greece)

Author keywords

Clinical; Experimental studies; Myocardial infarct size; Pharmacological agents; Postconditioning; Preconditioning

Indexed keywords

5 (N ETHYL N ISOPROPYL)AMILORIDE; 5 (N,N DIMETHYL)AMILORIDE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ACETYLCHOLINE; ADENOSINE; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A2B RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; BAY 60 6583; BENZOPYRAN DERIVATIVE; BMS 191095; BRADYKININ; CALCIUM SENSITIZER; CARIPORIDE; DIAZOXIDE; ENIPORIDE; KI 3315; LEVOSIMENDAN; MRS 1543; N (2 ACETOXYETHYL)NICOTINAMIDE; N (4 CHLOROPHENYL) N' CYANO N'' (6 CYANO 3,4 DIHYDRO 3 HYDROXY 2,2 DIMETHYL 2H 1 BENZOPYRAN 4 YL)GUANIDINE; N CYANO N' (2 NITROXYETHYL) 3 PYRIDINECARBOXIMIDAMIDE; NICORANDIL; OPIATE; PHENYLISOPROPYLADENOSINE; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; CARDIOTONIC AGENT;

ACUTE HEART FAILURE; ADJUVANT THERAPY; BLOOD CLOT LYSIS; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC PRECONDITIONING; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; POSTCONDITIONING ISCHEMIA; POSTOPERATIVE COMPLICATION; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN;

CARDIOTONIC AGENTS; DRUG DESIGN; HUMANS; ISCHEMIC PRECONDITIONING; MOLECULAR STRUCTURE; MYOCARDIAL INFARCTION;

EID: 61549087860     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986708786848550     Document Type: Review

References (87)

1. Hearse, D.J.; Bolli, R. Reperfusion induced injury: Manifestations, mechanisms, and clinical relevance. Cardiovasc. Res., 1992, 26, 101-8.
2. Verma, S.; Fedak, P.W.M.; Weisel, R.D.; Butany, J.; Rao, V.; Maitland, A.; Li, R.K.; Dhillon, B.; Yau, T.M. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation, 2002, 105, 2332-6.
3. Murry, C.E.; Jennings, R.B.; Reimer, K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation, 1986, 74, 1124-36.
4. Downey, J.M.; Davis, A.M.; Cohen, M.V. Signaling pathways in ischemic preconditioning. Heart Fail. Rev., 2007, 12, 181-8.
5. Yellon, D.M.; Alkhulaifi, A.M.; Pugsley, W.B. Preconditioning the human myocardium. Lancet, 1993, 342, 276-7.
6. Ottani, F.; Galvani, M.; Ferrini, D.; Corbello, F.; Limoneti, P.; Pantoli, D.; Rusticani, F. Prodroma angina limits infarct size; a role for ischemic preconsitioning. Circulation, 1995, 91, 291-7.
7. Kloner, R.A.; Bolli, R.; Marban, E.; Reinlib, L.; Braunwald, E. Medical and cellular implications of stunning, hibernation and preconditioning. An NHLBI Workshop. Circulation, 1998, 97, 1848-67
8. Sanada, S.; Kitakaze, M. Ischemic preconditioning: Emerging evidence, controversy, and translational trials. Intern. J. Cardiol., 2004, 97, 263-76.
9. Yellon, D.M.; Downey, J.M. Preconditioning the myocardium: From cellular physiology to clinical cardiology. Physiol. Rev., 2003, 83, 1113-51.
10. Oldenburg, O.; Qin, Q.; Krieg, T.; Yang, X.M.; Philipp, S.; Critz, S.D.; Cohen, M.V.; Downey, J.M. Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. Am. J. Physiol. Heart Circ. Physiol., 2004, 286, H468-76.
11. Eisen, A.; Fisman, E.Z.; Rubenfire, M.; Freimark, D.; McKechnie, R.; Tenenbaum, A.; Motro, M.; Adler, Y. Ischemic preconditioning: Nearly two decades of research. A comprehensive review. Atherosclerosis, 2004, 172, 201-10.
12. Liu, G.S.; Thornton, J.; Van Winkle, D.M.; Stanley, A.W.; Olsson, R.A.; Downey, J.M. Protection against infarction afforded by prevolatile conditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation, 1991, 84, 350-6.
13. Ytrehus, K.; Liu, Y.; Downey, J.M. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am. J. Physiol., 1994, 266, H1145-52.
14. Vegh, A.; Szekeres, L.; Parratt, J. Preconditioning of the ischemic myocardium: Involvement of the L-argine nitric oxide pathway. Br. J. Pharmacol., 1992, 107, 648-52.
15. Horimoto, H.; Gaudette, C.R.; Krukenkamp, I.B. Nitric oxide is a requisite cofactor to generate ATP sensitive potassium channel mediated preconditioning. Surg. Forum, 1998, 48, 202-6.
16. Hausenloy, D.J.; Yellon, D.M. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc. Res., 2006, 70, 240-53.
17. Tritto, I., D'Andrea, D.; Eramo, N.; Scognamiglio, A.; De Simone, C.; Violante, A.; Esposito, A.; Chiariello, M.; Ambrosio, G. Oxygen radicals can induce preconditioning in rabbit hearts. Circ. Res., 1997, 80, 743-8.
18. Ytrehus, K.; Walsh, R.S.; Richards, S.C.; Downey, J.M. Hydrogen peroxide as a protective agent during reperfusion. A study in the isolated perfused rabbit heart subjected to regional ischemia. Cardiov. Res., 1995, 30, 1033-7.
19. Sun, J.Z.; Tang, X.L.; Park, S.W.; Qiu, Y.; Turrens, J.F.; Bolli, R. Evidence for an essential role of reactive oxygen species in the genesis of late preconditioning against myocardial stunning in conscious pigs. J. Clin. Investig., 1996, 97, 562-76.
20. Ockaili, R.; Emani, V.R.; Okubo, S.; Brown, M.H.; Krottapalli, K.; Kukreja R.C. Opening of mitochondrial KATP channel induces early and delayed cardioprotective effect: Role of nitric oxide. Am. J. Physiol., 1999, 277, H2425-34.
21. Kukreja, R.C. Essential role of oxygen radicals in delayed pharmacological preconditioning. J. Mol. Cell Cardiol., 2001, 33, 1395-8.
22. Gross, G.J.; Fryer, R.M. Mitochondrial K(ATP) channels: Triggers or distai effectors of ischemic or pharmacological preconditioning? Circ. Res., 2000, 87, 431-3.
23. Schulz, R.; Cohen, M.D.; Behrends, M.; Downey, J. M.; Heusch, G. Signal transduction of ischemic preconditioning. Cardiovasc. Res., 2001, 52, 181-98.
24. ATP channels. Circ. Res., 2001, 89, 273-78.
25. Philipp, S.; Yang, X-M.; Cui, L.; Davis, A.M.; Downey, J.M.; Cohen, M. V. Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc. Res., 2006, 70, 308-14.
26. Yellon, D.M.; Hausenloy, D.J. Myocardial reperfusion injury. New Engl. J. Med., 2007, 357, 1121-35.
27. Vinten-Johansen, J. Postconditioning: A mechanical maneuver that triggers biological and molecular cardioprotective responses to reperfusion. Heart Fail. Rev., 2007, 12, 235-44
28. Zhao, Z.Q.; Corvera, J.S.; Halkos, M.E.; Kerendi, F.; Wang, N.P., Guyton, R.A.; Vinten-Johansen, J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol., 2003, 285, H579-88.
29. Kin, H.; Zatta, A.J.; Lofye, D.J.; Amerson, B.S.; Halkos, M.E.; Kerendi, F.; Zhao, Z.Q.; Guyton, R.A.; Headrick, J. P.; Vinten-Johansen; J. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc. Res., 2005, 67, 124-33.
30. Tsang, A.; Hausenloy, D.J.; Macanu, M.M.; Yellon, D,M. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ. Res., 2004, 95, 230-2.
31. Yang, X.M.; Philipp, S.; Downey, J.M.; Cohen, M.V. Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation Basic Res. Cardiol., 2005, 100, 57-63.
32. Iliodromitis, E.K.; Zoga, A.; Vrettou, A.; Andreadou, I.; Paraskevaidis, I.A.; Kaklamanis, L.; Kremastinos, D.Th. The effectiveness of postconditioning and preconditioning on infarct size in hypercholesterolemic and normal anesthetized rabbits. Atherosclerosis, 2006, 188, 356-62.
33. Iliodromitis, E.K.; Georgiadis, M.; Cohen, M.V.; Downey, J.M.; Bofilis, E.; Kremastinos, D.Th. Protection from post-conditionin g depends on the number of short ischemic insults in anesthetized pigs. Basic Res. Cardiol., 2006, 101, 502-7.
34. Cohen, M.V.; Yang, X.M.; Downey, J.M. The pH hypothesis of postconditioning: Staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation, 2007, 115, 1895-903.
35. Lemasters, J.J.; Bond, J.M.; Chacon, E.; Harper, I.S.; Kaplan, S.H.; Ohata, H.; Trollinger, D.R.; Herman, B.; Cascio, W.E. The pH paradox in ischemia-reperfusion injury to cardiac myocytes. EXS, 1996, 76, 99-114.
36. Penna, C.; Rastaldo, R. Mancardi, D.; Raimondo, S., Cappello, S.; Gattullo, D.; Losano, G.; Pagliaro, P. Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K+ channel and protein kinase C activation. Basic Res. Cardiol., 2006, 101, 180-9.
37. Liu, Y; Yang, X.M.; Iliodromitis, E.K.; Kremastinos, D.Th.; Dost, T.; Cohen, M.V.; Downey, J.M. Redox signaling at reperfusion is required for protection from ischemic preconditioning but not from a direct PKC activator. Basic Res. Cardiol., 2008, 103, 54-9
38. Kin, H.; Zhao, Z.Q.; Sun, H. Y.; Wang, N. P.; Corvera, J.S., Halkos, M.E.; Kerendi, F., Guyton, R.A.; Vinten-Johansen, J. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfiision. Cardiovasc. Res., 2004, 62, 74-85.
39. Halkos, M.E.; Kerendi, F.; Corvera, J.S.; Wang, N.P.; Kin. H.; Payne, C. S.; Sun, H. Y.; Guyton, R.A.; Vinten-Johansen. J.; Zhao. Z.Q. Myocardial protection with postconditioning is not enhanced by ischemic preconditioning. Ann. Thor. Surg., 2004, 78, 961-9.
40. Mykytenko, J.; Kerendi, F.; Reeves, J.G.; Kin, H.; Zatta, A.J.; Jiang, R., Guyton, R.A.; Vinten-Johansen, J.; Zhao, Z.Q. Long-term inhibition of myocardial infarction by postconditioning during reperfusion. Basic Res. Cardrol., 2007, 102, 90-100.
41. Hausenloy, D.J., Yeilon, D.M. Clinical translation of cardioprotective strategies: Report and recommendations of the Hatter Institute 5th International Workshop on Cardioprotection. Basic Res. Cardiol., 2008, 103, 493-500.
42. Mahaffey., K.W.; Puma, J.A.; Bardagelata, N.A.; Dicarli, N.P.; Leeser, M.A.; Browne, K.F., Eisenberg, P.R.; Bolli, R.; Casas, A.C.; Molina-Viamonte, V.; Orlandi, C., Blevins, R.; Gibbons, R.J.; Califf, R.M.; Granger, C.B. Adenosine as an adjunct to thrombolytic therapy for acute mydcardial infarction: Results of a multicenter, randomized, placebo-controlled trial: The Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J. Am. Coll. Cardiol., 1999, 34, 1711-20.
43. Ross, A.M.; Gibbons, R.J.; Stone, G.W. Amistad II investigators. A randomized, double-blind, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J. Am. Coll. Cardiol., 2005, 45, 1775-80.
44. Mentzer, Jr, R.M.; Rahko, P.S.; Molina-Viamonte, V.; Canver, C.C.; Chopra, P.S.; Love, R.B. Safety, tolerance, and efficacy of adenosine as an additive to blood cardioplegia in humans during coronary artery bypass surgery. Am. J Cahiiol., 1997, 79, 38-43
45. Mentzer, Jr R.M.; Birjiniuk, V., Khuri, S.; Lowe, J.E.; Rahko, P.S.; Weisel, R.D. Adenosine myocardial protection: Preliminary results of a phase II clinical trial. Ann. Surg., 1999, 229, 649-50.
46. Lasley, R.D.; Mentzer, Jr R.M. Preconditioning and its potential role in myocardial protection during cardiac surgery. J. Card. Surg., 1995, 10, 349-53.
47. Mangano, D. T.; Miao, Y.; Tudor, I.C.; Dietzel, C. Post-reperfusion myocardial infarction. Long -term survival improvement using adenosine regulation with acadesine. J Am. Coll. Cardiol., 2006, 48, 206-14.
48. Patel, D.J., Pucell, H.J.; Fox, K.M. Cardioprotection by opening of the KATP channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. Eur Heart J., 1999, 20, 51-7.
49. The IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: The impact of nicorandil in angina (IONA) randomized trial. Lancet, 2002, 359, 1269-1275
50. Ota, S.; Nishikawa, H.; Takeuchi, M.; Nakamura, T.; Okamoto, S.; Setsuda, M.; Makino, K.; Yamakado, T.; Nakano, T. Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ. J., 2006, 70, 1099-104.
51. Xu, Z.; Jang, Y.; Mueller, R.A.; Norfleet, E.A. IB-MECA and cardioprotection. Cardiavasc. Drug Rev., 2006, 24, 227-38.
52. Jacobson, K.A.; Xie, R.; Young, L.; Chang, L.; Liang, B.T. A novel pharmacological approach to treating cardiac ischemia. Binary conjugates of A1 and A3 adenosine receptor agonists. J. Biol. Chem., 2000, 275, 30272-9.
53. Solenkova, N.V.; Solodushko, V.; Cohen, M.; Downey, J.M. Endogenous adenosine protects preconditioned heart during early minutes of reperfusion by activating Akt. Am. J. Physiol. Heart Circ. Physiol., 2006, 290, H441-9.
54. Kuno, A.; Critz, S.D.; Cui, L.; Solodunsko, V.; Yang, X.M.; Krahn, T.; Albrecht, B.; Philipp, S.; Cohen, M.V.; Downey, J.M. Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J. Mol. Cell Cardiol., 2007, 43, 262-71.
55. Eckle, T.; Krahn, T.; Grenz, A.; Kohler, D.; Mittelbronn, M.; Ledent, C.; Jacobson, M.A.; Osswald, H.; Thompson, L.F.; Unertl, K.; Eltzschig, H.K. Cardioprotection by ecto-5′-nucleotidase (CD73) and A2B adenosine receptors. Circulation, 2007, 115, 1581-90.
56. Mannhold, R. KATP channel openers: Structure-Activity relationships and therapeutic potential. Med. Res. Rev., 2004, 24, 213-66.
57. Kato, T.; Yoshimoto, N. Ischaemic preconditioning and outcomes after angioplasty: Effects of drug therapy. Drugs, 2003, 63, 133-8.
58. Ishibashi, T.; Hamaguchi, M.; Imai, S. 2-Nicotinamidoethyl acetate (SG-209) is a potassium channel opener: Structure activity relationship among nicorandil derivatives. Naunyn- Schmiedeberg's Arch. Pharmacol., 1991, 344, 235-9.
59. Ishibashi, T.; Hamaguchi, M.; Imai, S. Vasodilating properties of KRN2391: Structural basis of a new pyridine-type potassium channel opener with a nitrate moiety. Naunyn-Schmiedeberg's Arch. Pharmacol., 1992, 346, 94-101.
60. Fotopoulou, T.; Iliodromitis, E.K.; Koufaki, M.; Tsotinis, A.; Zoga, A.; Gizas, V.; Pyriochou, A.; Papapetropoulos, A.; Andreadou, I.; Kremastinos, D.Th. Design and synthesis of nitrate esters of aromatic heterocyclic compounds as pharmacological preconditioning agents. Bioorg. Med. Chem., 2008, 16, 4523-31.
61. Rovnyak, G. C.; Ahmed, S. Z.; Ding, C. Z.; Dzwonczyk, S.; Ferrara, F. N.; Humphreys, W. G.; Grover, G. J.; Santafianos, D.; Atwal, K. S.; Baird, A. J.; McLaughlin, L. G.; Normandin, D. E.; Sleph, P. G.; Traeger, S. C. Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity. J. Med. Chem., 1997, 40, 24-34.
62. Grover, G.J.; D'Alonzo, A.J.; Garlid, K.D.; Bajgar, R.; Lodge, N.J.; Sleph, P.G.; Darbenzio, R.B.; Hess, T.A.; Smith, M.A.; Paucek, P.; Atwal, K.S. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity. J. Pharmacol. Exp. Ther., 2001, 297, 1184-92.
63. Jung, Y.S.; Jung, Y.S.; Kim, M.Y.; Kim, M.H.; Lee, S.; Yi, K.Y.; Yoo, S.E.; Lee, S.H.; Baik, E.J.; Moon, C.H.; Cho, J.P. KR-31466, a benzopyranylindol analog, attenuates hypoxic injury through mitochondrial K(ATP) channel and protein kinase C activation in heart-derived H9c2 cells. J. Pharmacol. Sci., 2003, 92, 13-8.
64. Broadhead, M.W.; Kharbanda, R.K.; Peters, M.J.; MacAllister, R.J. KATP channel activation induces ischemic preconditioning of the endothelium in humans in vivo. Circulation, 2004, 110, 2077-82.
65. Parissis, J.T.; Andreadou, I.; Bistola, V.; Paraskevaidis, I.; Filippatos, G.; Kremastinos, D.T. Novel biologic mechanisms of levosimendan and its effect on the failing heart. Exp. Opin. Investig. Drugs, 2008, 17, 1143-50.
66. Kass, D.A.; Solaro, R.J. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation, 2006, 113, 305-15.
67. Parissis, J.T.; Filippatos, G.; Farmakis, D.; Adamopoulos, S.; Paraskevaidis, I.; Kremastinos, D. Levosimendan for the treatment of acute heart failure syndromes. Expert Opin. Pharmacother., 2005, 6, 2741-51.
68. Takahashi, R.; Endoh, M. Dual regulation of myofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium. Br. J. Pharmacol., 2005, 145, 1143-52.
69. Kopustinskiene, D.M.; Pollesello, P.; Saris, N.E. Levosimendan is a mitochondrial K(ATP) channel opener. Eur. J. Pharmacol., 2001, 428, 311-4.
70. Hasenfuss, G.; Pieske, B.; Castell, M.; Kretschmann, B.; Maier, L.S.; Just, H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation, 1998, 98, 2141-7.
71. Yokoshiki, H.; Katsube, Y.; Sunagawa, M.; Sperelakis, N. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J. Pharmacol. Exp. Ther., 1997, 283, 375-83.
72. Kersten, J.R.; Montgomery, M.W.; Pagel, P.S.; Warltier, D.C. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth. Analg. 2000, 90, 5-11.
73. Duan, J.; Karmazyn, M. Protective effects of amiloride on the ischemic reperfused rat heart. Relation to mitochondrial function. Eur. J. Pharmacol., 1992, 210, 149-57.
74. Meng, H.; Pierce, G. Protective effects of 5-(N,N-dimethyl) amiloride on ischemia-reperfusion injury in hearts. Am. J. Physiol., 1990, 258, H1615-9.
75. Sato, H.; Miki, T.; Vallabhapurapu, R. P.; Wang, P.; Liu, G. S.; Cohen, M. V.; Downey, J. M. The mechanism of protection from 5 (N-ethyl-N-isopropyl)amiloride differs from that of ischemic pre-conditioning in rabbit heart. Basic Res. Cardiol., 1997, 92, 339-50.
76. Munch-Ellingsen, J.; Løkebø, J. E.; Bugge, E.; Ytrehus, K. Equal reduction in infarct size by ethylisopropyl-amiloride pretreatment and ischemic preconditioning in the in situ rabbit heart. Mol. Cell Biochem., 1998, 186, 13-8.
77. Goldberg, S.P.; Digerness, S.B.; Skinner, J.L.; Killingsworth, C.R.; Katholi, C.R.; Holman, W.L. Ischemic preconditioning and Na+/H+ exchange inhibition improve reperfusion ion homeostasis. Ann. Thorac. Surg., 2002, 73, 569-74.
78. Castellá, M.; Buckberg, G. D.; Tan, Z.; Ignarro, L. J. Myocyte and endothelial effects of preconditioning the jeopardized heart by inhibiting Na/H exchange. J. Thorac. Cardiovasc. Surg., 2002, 124, 1113-21.
79. Gumina, R. J.; Moore, J.; Schelling, P.; Beier, N.; Gross, G. J. Na(+)/ H(+) exchange inhibition prevents endothelial dysfunction after I/R injury. Am. J. Physiol. Heart Circ. Physiol., 2001, 281, H1260-66.
80. Yamamoto, S.; Matsui, K.; Sasabe, M.; Ohashi, N. Effect of an orally active Na+/H+ exchange inhibitor, SMP-300, on experimental angina and myocardial infarction models in rats. J. Cardiovasc. Pharmacol., 2002, 39, 234-41.
81. Kusumoto, K.; Igata, H.; Abe, A.; Ikeda, S.; Tsuboi, A.; Imamiya, E. Fukumoto, S.; Shiraishi, M.; Watanabe T. In vitro and in vivo pharmacology of a structurally novel Na+-H+ exchange inhibitor, T-162559. Br. J. Pharmacol., 2002, 135, 1995-2003
82. Pollesello, P.; Papp, Z. The cardioprotective effects of levosimendan: preclinical and clinical evidence. J. Cardiovasc. Pharmacol., 2007, 50, 257-63.
83. Weber, N. C.; Preckel, B.; Schlack, W. The effect of anaesthetics on the myocardium-new insights into myocardial protection. Eur. J. Anaesth., 2005, 22, 647-57.
84. Vinten-Johansen J.; Zhao Z.Q.; Jiang R.; Zatta A.J.; Dobson G.P. Preconditioning and postconditioning: Innate cardioprotection from ischemia-reperfusion injury. J. Appl. Physiol., 2007, 103, 1441-8.
85. Chiari, P.C.; Bienengracher, M.W.; Pagel, P.S.; Krolikowski, J.G.; Kersten, J.R.; Waltier, D.C. Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: Evidence for anesthetic-induced postconditioning in rabbits. Anesthesiology, 2005, 102, 102-9.
86. Feng, J.; Fischer, G.; Lucchinetti, E.; Zhu, M.; Bestmann, L.; Jegger, D.; Arras, M.; Pasch, J.; Perriard, J.C.; Schaub, M.C.; Zaung, M. Infarct-remodeled myocardium is receptive to protection by isoflurane postconditioning: Role of protein kinase B/Akt signaling. Anesthesiology, 2006, 104, 1004-14.
87. Krolikowski, J.G.; Weihrauch, D.; Bienengracher, M.; Kersten, J.R.; Warltier, D.C.; Pagel, P.S. Role of Erk1/2, p70s6K, and eNOS in isoflurane-induced cardioprotection during early reperfusion in vivo. Can. J. Anaesth., 2006, 53, 174-82.